InicioAMPH • NASDAQ
add
Amphastar Pharmaceuticals Inc
Cierre anterior
26,45 $
Intervalo diario
26,44 $ - 27,12 $
Intervalo anual
20,39 $ - 39,01 $
Cap. bursátil
1231,98 M USD
Volumen medio
418,91 mil
Relación precio-beneficio
11,89
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (USD) | sept 2025info | Cambio interanual |
|---|---|---|
Ingresos | 191,84 M | 0,33 % |
Gastos operativos | 50,23 M | 11,88 % |
Ingresos netos | 17,35 M | -57,09 % |
Margen de beneficio neto | 9,04 | -57,24 % |
Beneficios por acción | 0,93 | -3,12 % |
EBITDA | 62,55 M | -11,21 % |
Tipo impositivo efectivo | 19,35 % | — |
Balance general
Activos totales
Responsabilidades totales
| (USD) | sept 2025info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 276,21 M | 10,27 % |
Activos totales | 1666,22 M | 7,83 % |
Responsabilidades totales | 889,48 M | 8,80 % |
Patrimonio total | 776,75 M | — |
Acciones en circulación | 45,95 M | — |
Precio-valor contable | 1,58 | — |
Rentabilidad económica | 7,38 % | — |
Retorno sobre capital | 8,50 % | — |
Flujo de caja
Variación neta del flujo de caja
| (USD) | sept 2025info | Cambio interanual |
|---|---|---|
Ingresos netos | 17,35 M | -57,09 % |
Efectivo de operaciones | 52,58 M | -12,31 % |
Efectivo de inversión | -19,62 M | 43,27 % |
Efectivo de financiación | -4,35 M | 80,95 % |
Variación neta del flujo de caja | 28,58 M | 1.044,41 % |
Flujo de caja libre | 58,63 M | 133,97 % |
Información sobre la empresa
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
Fundación
1996
Sitio web
Empleados
2.028
